Literature DB >> 15675718

Neuroimaging methods applied in Parkinson's disease.

Klaus L Leenders1.   

Abstract

Radiotracer methods provide regional in vivo quantified information about specific biochemical activities in brain tissue. The understanding of the principles governing radiotracer uptake into brain tissue determines the potential value of these tracers in assessing pathophysiology of brain diseases. Too often a reductionist view of images is taken to directly point to clinical features or even diagnoses of brain diseases. Parkinson's disease like many other neurodegenerative brain diseases is a multisystem disorder of considerable biological and clinical complexity while the information given by regional cerebral tracer uptake points to a momentary biochemical local tissue feature. Examples applying to the well-known dopaminergic tracers are given.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15675718     DOI: 10.1007/s00415-004-1603-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  14 in total

1.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Authors:  K Marek; R Innis; C van Dyck; B Fussell; M Early; S Eberly; D Oakes; J Seibyl
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

Review 2.  Do dopamine agonists or levodopa modify Parkinson's disease progression?

Authors:  K Marek; D Jennings; J Seibyl
Journal:  Eur J Neurol       Date:  2002-11       Impact factor: 6.089

3.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

4.  Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.

Authors:  W P Melega; A Luxen; M M Perlmutter; C H Nissenson; M E Phelps; J R Barrio
Journal:  Biochem Pharmacol       Date:  1990-06-15       Impact factor: 5.858

5.  Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

Authors:  E Nurmi; H M Ruottinen; J Bergman; M Haaparanta; O Solin; P Sonninen; J O Rinne
Journal:  Mov Disord       Date:  2001-07       Impact factor: 10.338

6.  The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

Authors:  K L Leenders; E P Salmon; P Tyrrell; D Perani; D J Brooks; H Sager; T Jones; C D Marsden; R S Frackowiak
Journal:  Arch Neurol       Date:  1990-12

7.  Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.

Authors:  E Nurmi; J Bergman; O Eskola; O Solin; S M Hinkka; P Sonninen; J O Rinne
Journal:  J Cereb Blood Flow Metab       Date:  2000-11       Impact factor: 6.200

8.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

9.  Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

Authors:  Marek Droździk; Monika Białecka; Katarzyna Myśliwiec; Krystyna Honczarenko; Jan Stankiewicz; Zbigniew Sych
Journal:  Pharmacogenetics       Date:  2003-05

10.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.

Authors:  R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.